Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Three outstanding young scientists named July 2012 Damon Runyon-Sohn Fellows

Three outstanding young scientists named July 2012 Damon Runyon-Sohn Fellows

Targeting CDK1 pathway may be efficacious for acute myeloid leukemias with FLT3 mutation

Targeting CDK1 pathway may be efficacious for acute myeloid leukemias with FLT3 mutation

IDH mutation drives aggressive form of acute myeloid leukemia

IDH mutation drives aggressive form of acute myeloid leukemia

Maraviroc reduces incidence of GvHD in blood cancer patients after bone marrow transplantation

Maraviroc reduces incidence of GvHD in blood cancer patients after bone marrow transplantation

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

Thrombopoietin mimetic offers aplastic anemia hope

Thrombopoietin mimetic offers aplastic anemia hope

DRCRF names 21 new Damon Runyon Fellows

DRCRF names 21 new Damon Runyon Fellows

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Blocking a fundamental process deep within cancer cells can selectively kill them

Blocking a fundamental process deep within cancer cells can selectively kill them

Targeting double-stranded RNA dependent protein kinase could treat inflammation

Targeting double-stranded RNA dependent protein kinase could treat inflammation

Conference highlights utility of zebrafish for human disorder studies

Conference highlights utility of zebrafish for human disorder studies

MiR-125b downregulated in both aggressive and indolent forms of CLL

MiR-125b downregulated in both aggressive and indolent forms of CLL

Insight into understanding IDH mediated disease

Insight into understanding IDH mediated disease

Scientists identify causative link between oncometabolite and onset of AML

Scientists identify causative link between oncometabolite and onset of AML

NOTCH1 signaling promotes T-cell acute lymphoblastic leukemia-initiating cell regeneration

NOTCH1 signaling promotes T-cell acute lymphoblastic leukemia-initiating cell regeneration

Researchers identify new gene target for leukemia therapy

Researchers identify new gene target for leukemia therapy

Abnormal bone marrow stem cells drive development of myelodysplastic syndromes

Abnormal bone marrow stem cells drive development of myelodysplastic syndromes

CytRx granted European patent for tumor-targeting linker platform technology

CytRx granted European patent for tumor-targeting linker platform technology

Safer alternative to experimental gene therapy against HIV infection

Safer alternative to experimental gene therapy against HIV infection

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.